A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

NCT04595409 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: FYB202 (Proposed ustekinumab biosimilar)
DRUG: Stelara® (Ustekinumab)

Sponsor

Bioeq GmbH